quinuclidines has been researched along with Sarcoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Badalamenti, G; Bazan, V; Casarin, A; De Luca, I; Incorvaia, L; Messina, C; Musso, E; Ricciardi, MR; Russo, A | 1 |
| Aoki, Y; Hayashi, K; Higuchi, T; Igarashi, K; Inatani, H; Kato, T; Kimura, H; Nishida, H; Shimozaki, S; Shirai, T; Takeuchi, A; Tanzawa, Y; Tsuchiya, H; Yamamoto, N | 1 |
| Chaire, V; Chibon, F; Grellety, T; Italiano, A; Lagarde, P; Laroche-Clary, A; Neuville, A | 1 |
1 trial(s) available for quinuclidines and Sarcoma
| Article | Year |
|---|---|
Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-da
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Bone Neoplasms; Cross-Over Studies; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Quinuclidines; Sarcoma; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting; Young Adult | 2015 |
2 other study(ies) available for quinuclidines and Sarcoma
| Article | Year |
|---|---|
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Pilot Projects; Prospective Studies; Pyridines; Quinuclidines; Receptors, Neurokinin-1; Sarcoma; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2019 |
PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Humans; Inhibitory Concentration 50; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Quinuclidines; Reactive Oxygen Species; Sarcoma; Tumor Suppressor Protein p53 | 2015 |